Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Policy / Pricing
  • FDA’s leadership void leaves biotech with renewed ‘uncertainty’
  • Policy / Pricing

FDA’s leadership void leaves biotech with renewed ‘uncertainty’

BioPharma Dive

Marty Makary's resignation leaves the agency with temporary directors in three top positions, and a number of newly instituted policies with an unclear future.

Read full story

pharminent May 13, 2026 (Last updated: May 16, 2026)

BioPharma Dive

Marty Makary’s resignation leaves the agency with temporary directors in three top positions, and a number of newly instituted policies with an unclear future.

Read full story

Post navigation

Previous: UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged
Next: Joint MHRA/NICE pathway ‘benefits industry over patients’

Related Stories

  • Policy / Pricing

Mid-cap biotechs join Trump’s latest round of drug pricing deals

pharminent September 1, 2026
  • Policy / Pricing

MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones

pharminent August 27, 2026
  • Policy / Pricing

MFN affecting Swiss medicines access, says Interpharma

pharminent August 13, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.